PMID- 36419114
OWN - NLM
STAT- MEDLINE
DCOM- 20221125
LR  - 20221213
IS  - 1472-6823 (Electronic)
IS  - 1472-6823 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Nov 22
TI  - Durvalumab-induced thyroiditis in a patient with non-small cell lung carcinoma: a 
      case report and review of pathogenic mechanisms.
PG  - 291
LID - 10.1186/s12902-022-01190-5 [doi]
LID - 291
AB  - BACKGROUND: Immune checkpoint inhibitors (ICI) targeting cytotoxic 
      T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 and 
      its ligand (PD-1/PD-L1) have become the current standard-of-care for advanced 
      cancers. This novel therapeutic approach comes with its costs in the form of 
      immune-related adverse events (irAE), including endocrinopathy. CASE 
      PRESENTATION: A 63-year-old woman was diagnosed with a non-small cell lung 
      carcinoma of the right superior lobe, cT3N2M0. She developed thyrotoxicosis 
      followed by hypothyroidism induced by consolidation immunotherapy with durvalumab 
      (anti-PD-L1). Analysis of the human leukocyte antigen (HLA) region showed HLA-DR4 
      (susceptible) and DR13 (protective). The possible mechanisms are subsequently 
      discussed in detail. CONCLUSIONS: The case of a patient with thyroiditis 
      associated with the PD-L1 inhibitor durvalumab is described, highlighting the 
      need for proactive monitoring of thyroid hormone levels. Identifying biomarkers 
      associated with an increased risk of ICI-induced side effects (such as HLA) is of 
      interest for better patient selection, optimal management and improved 
      understanding of the mechanisms involved.
CI  - (c) 2022. The Author(s).
FAU - de Filette, Jeroen M K
AU  - de Filette JMK
AUID- ORCID: 0000-0003-3906-264X
AD  - Department of Endocrinology, Brugmann University Hospital, Universite Libre de 
      Bruxelles, Brussels, Belgium. jeroen.defilette@chu-brugmann.be.
AD  - Department of Endocrinology, UZ Brussel, Laarbeeklaan 101, 1090, Brussels, 
      Belgium. jeroen.defilette@chu-brugmann.be.
FAU - Andre, Stephanie
AU  - Andre S
AD  - Department of Pulmonary Medicine, Saint-Pierre University Hospital, Rue Haute 
      322, 1000, Brussels, Belgium.
AD  - Universite Libre de Bruxelles, Brussels, Belgium.
AD  - Department of Pulmonary Medicine, Brugmann University Hospital, Brussels, 
      Belgium.
FAU - De Mey, Lynn
AU  - De Mey L
AD  - Department of Nuclear Medicine, UZ Brussel, Laarbeeklaan 101, 1090, Brussels, 
      Belgium.
FAU - Aspeslagh, Sandrine
AU  - Aspeslagh S
AD  - Department of Medical Oncology, Vrije Universiteit Brussel (VUB), Universitair 
      Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium.
FAU - Karmali, Rafik
AU  - Karmali R
AD  - Department of Endocrinology, UZ Brussel, Laarbeeklaan 101, 1090, Brussels, 
      Belgium.
FAU - Van der Auwera, Bart J
AU  - Van der Auwera BJ
AD  - Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium.
FAU - Bravenboer, Bert
AU  - Bravenboer B
AD  - Department of Endocrinology, Brugmann University Hospital, Universite Libre de 
      Bruxelles, Brussels, Belgium.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20221122
PL  - England
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
RN  - 28X28X9OKV (durvalumab)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - *Thyroiditis/chemically induced
MH  - Antibodies, Monoclonal/adverse effects
MH  - Immune Checkpoint Inhibitors/adverse effects
MH  - *Lung Neoplasms/drug therapy
PMC - PMC9682778
OTO - NOTNLM
OT  - Case Report
OT  - Durvalumab
OT  - HLA
OT  - Immune Checkpoint Inhibitors
OT  - Thyroiditis
COIS- The authors declare that they have no competing interests.
EDAT- 2022/11/25 06:00
MHDA- 2022/11/26 06:00
PMCR- 2022/11/22
CRDT- 2022/11/24 00:16
PHST- 2021/08/29 00:00 [received]
PHST- 2022/10/26 00:00 [accepted]
PHST- 2022/11/24 00:16 [entrez]
PHST- 2022/11/25 06:00 [pubmed]
PHST- 2022/11/26 06:00 [medline]
PHST- 2022/11/22 00:00 [pmc-release]
AID - 10.1186/s12902-022-01190-5 [pii]
AID - 1190 [pii]
AID - 10.1186/s12902-022-01190-5 [doi]
PST - epublish
SO  - BMC Endocr Disord. 2022 Nov 22;22(1):291. doi: 10.1186/s12902-022-01190-5.